Published by Iain Gilbert on 27th October 2022
(Sharecast News) - Drugmaker GSK revealed on Thursday that it will not proceed with regulatory submissions of its experimental treatment for moderate-to-severe rheumatoid arthritis after the drug candidate failed to meet a key endpoint in a recent study.
URL: http://www.digitallook.com/dl/news/story/33064961/...